NASDAQ · Medical Devices · USD

Sera Prognostics, Inc. (SERA) Stock Analysis

Sera Prognostics, Inc. (SERA) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SERA

$2.03

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SERA with… →

SERA Key Statistics

As of Oct 21, 2026

Trading

Open: $2.03
Previous Close: $2.03
Day's Range: 2.03–2.05
52-Week Range: 1.56–3.95
Volume: 24.22K
Beta: 1.06

Valuation

Market Cap: $80.08M
P/E Ratio: unprofitable
P/S ratio: 1,144.03
EPS (ttm): −0.67

Financials (FY)

Revenue (FY): $81.00K+5.19%
Net Income (FY): −$31.93M
Shares Outstanding: 38.48M
1-Year Return: −39.58%

Dividend and dates

Earnings Date: November 4, 2026
Avg Volume: 23.97K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SERA closed at $2.03, −39.58% over 1 year.

Sera Prognostics, Inc. (SERA) has a market capitalization of $80.08M.

In fiscal 2025, SERA reported revenue of $81.00K.

SERA Stock Return by Calendar Year

Sera Prognostics, Inc. (SERA) return since Jul 2021: what $10,000 became

1 year: $10,000 $6,042; −39.58%
5 years: $10,000 $1,933; −80.67%
Since Jul 2021: $10,000 $1,706; −82.94%

If you had invested $10,000 in Sera Prognostics, Inc. (SERA) at the close on July 15, 2021, the earliest close on record here, it would have been worth $1,706 at the close on October 21, 2026: −82.94% in total, −28.52% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−42.27%−81.66%+374.60%+36.12%−63.76%−31.19%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−31.19%
2025	−63.76%
2024	+36.12%
2023	+374.60%
2022	−81.66%
2021 (partial year)	−42.27%

As of October 21, 2026.

SERA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$81.00K	−$31.93M	−39,417.3%
2024	$77.00K	−$32.90M	−42,724.7%
2023	$306.00K	−$36.24M	−11,843.8%
2022	$268.00K	−$44.19M	−16,487.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$81.00K	−$83.00K	−$36.50M	−$31.93M	−39,417.3%
2024	$77.00K	−$5.00K	−$36.64M	−$32.90M	−42,724.7%
2023	$306.00K	$96.00K	−$39.82M	−$36.24M	−11,843.8%
2022	$268.00K	$75.00K	−$45.65M	−$44.19M	−16,487.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SERA Valuation vs Medical Devices Median

Median of 145 stocks

Metric	SERA	Medical Devices median	vs median
P/S ratio	1,144.03	2.53	452.2x the median

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sera Prognostics, Inc. (SERA) is capitalised at $80.08M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 71.

SERA last closed at $2.03 on October 21, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $1.56 to $3.95. The latest close sits 30.13% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $81.00K. That is +5.19% against the prior fiscal year, when revenue was $77.00K. The same year closed with a net loss of $31.93M. Earnings per share on a trailing basis come to −0.67.

Across the 4 fiscal years on file, revenue moves from $268.00K in 2022 to $81.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1,144.03. On price-to-sales that is 452.2 times the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

The reported beta is 1.06. Annualized volatility over the trailing 5 years is 125.83%. The trailing one-year total return is −39.58%. Across 5 years the annualized return works out at −28.01%.

Growth & Income

The record shows no dividend for SERA.

The strongest complete calendar year on file is 2023 at +374.60%; the weakest is 2022 at −81.66%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −31.19%.

Peer Comparison

Sera Prognostics, Inc. (SERA) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Sera Prognostics, Inc.	SERA	$80.08M	—
Abbott Laboratories	ABT	$173.92B	32.4
Medtronic plc.	MDT	$119.00B	22.9
Stryker Corporation	SYK	$114.15B	30.8

The Medical Devices industry average P/E ratio is 27.1x. Sera Prognostics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

MDT

Medtronic plc.

$119.00B

SYK

Stryker Corporation

$114.15B

BSX

Boston Scientific Corporation

$64.33B

Edwards Lifesciences Corporation

$50.95B

GEHC

GE HealthCare Technologies Inc.

$31.17B

View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Sera Prognostics, Inc.

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Visit website →